ACTIVE_NOT_RECRUITING

Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.

Official Title

Does the Concept of the Sentinel Lymph Node Apply to Esophageal Cancer? A Prospective Assessment of Near-infrared Image-guided Lymphatic Mapping and Sentinel Lymph Node Identification in Esophageal Cancer

Quick Facts

Study Start:2020-05-20
Study Completion:2026-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04400292

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Pathological diagnosis of adenocarcinoma tumor located in distal 1/3 of esophagus or esophagogastric junction , with a plan to undergo minimally invasive esophagectomy.
  2. * All patients with Stage IVA (AJCC Cancer Staging Manual, 8th edition) disease will be eligible
  3. * ≥18 years of age.
  4. * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study and for standard surgical resection.
  1. * No plan to undergo surgical resection.
  2. * Severe iodide or seafood allergy.
  3. * Women of childbearing potential without a negative pregnancy test; or women who are lactating.
  4. * Prior diagnosis of severe hepatic or renal dysfunction.
  5. * Patients with Stage IVB or M1 disease (AJCC Cancer Staging Manual, 8th edition)
  6. * Patients with local recurrence and planning to undergo salvage esophagectomy

Contacts and Locations

Principal Investigator

Daniela Molena, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Daniela Molena, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-05-20
Study Completion Date2026-05

Study Record Updates

Study Start Date2020-05-20
Study Completion Date2026-05

Terms related to this study

Keywords Provided by Researchers

  • Sentinel Lymph Node Mapping
  • lymphadenectomy
  • esophagectomy
  • ICG Injection
  • Intraoperative NIR Imaging
  • 20-201

Additional Relevant MeSH Terms

  • Esophageal Cancer